Section 10 · Monograph

Ropinirole (RLS dosing)

Reviewed Nov 2026FDA label

RequipDopamine agonist

Indications

Moderate-to-severe primary Restless Legs Syndrome (RLS) in adults (FDA-approved indication, distinct from the Parkinson's disease indication covered in the separate general ropinirole/Parkinson's monograph). This entry addresses RLS-specific dosing and safety issues only.FDA-labeled

Ropinirole is a non-ergoline dopamine agonist with high specificity and full intrinsic activity at D2 and D3 dopamine receptor subtypes.
In RLS, the precise mechanism of benefit is not fully established but is thought to involve modulation of the same dopaminergic system implicated in RLS pathophysiology (in contrast to Parkinson's disease, where efficacy derives from stimulating postsynaptic striatal dopamine receptors to compensate for nigrostriatal dopamine deficiency).

RLS dosing range (0.25-4 mg/day) is distinct and substantially lower than the Parkinson's disease dosing range (up to 24 mg/day).
Take 1-3 hours before bedtime.
Titration schedule: Days 1-2: 0.25 mg; Days 3-7: 0.5 mg; Week 2: 1 mg; Week 3: 1.5 mg; Week 4: 2 mg; Week 5: 2.5 mg; Week 6: 3 mg; Week 7: 4 mg.
Maximum FDA-approved RLS dose: 4 mg once daily.
Smoking/smoking cessation: smoking induces CYP1A2 and increases ropinirole clearance by ~38%; patients who quit smoking during therapy may need dose reduction.
Check serum ferritin/iron studies before initiating dopaminergic therapy for RLS; correct iron deficiency first when present.

Renal impairment: mild-to-moderate impairment generally does not require adjustment; severe impairment and hemodialysis have not been studied.

Hepatic impairment: pharmacokinetics not studied in hepatic impairment; titrate with caution.

Known hypersensitivity to ropinirole or any component of the formulation (per FDA labeling, this is the only listed contraindication).

CYP1A2 is the principal metabolic pathway for ropinirole, making it susceptible to numerous interactions.
Ciprofloxacin (CYP1A2 inhibitor) — increases ropinirole AUC by 84% and Cmax by 60%; dose adjustment/monitoring needed.
Fluvoxamine and other CYP1A2 inhibitors — similarly increase ropinirole exposure; avoid combination or reduce dose substantially.
Estrogens (oral contraceptives, hormone therapy) — reduce ropinirole oral clearance by ~36%; dose adjustment may be needed.
Smoking — induces CYP1A2, lowering ropinirole levels.
Dopamine antagonists (antipsychotics, metoclopramide) — may reduce ropinirole efficacy.
CNS depressants/alcohol — additive sedation, increased risk of sudden sleep episodes.

Very common (RLS trials): nausea (40% vs. 8% placebo), somnolence (12% vs. 6%), vomiting (11% vs. 2%), dizziness (11% vs. 5%), fatigue (8% vs. 4%).
Sudden sleep onset during activities of daily living, including driving, sometimes without perceived warning signs.
Orthostatic hypotension, most pronounced during forced/rapid dose titration; monitor especially early in titration.
Hallucinations are uncommon in RLS populations specifically but occur more often in Parkinson's disease populations.
Impulse control disorders: gambling urges, hypersexuality, compulsive spending/eating; screen directly at follow-up.
AUGMENTATION (RLS-specific, clinically critical): chronic ropinirole therapy can cause augmentation — earlier onset of symptoms, increased symptom severity, shortened rest-onset latency, and spread of symptoms to previously unaffected limbs/trunk. A related phenomenon, early-morning rebound, is also described. Management: avoid simply increasing the dose; consider earlier/split dosing, iron repletion, or transition to a non-dopaminergic agent (e.g., gabapentin enacarbil) with gradual taper.
Discontinuation: gradual taper recommended; abrupt cessation of dopaminergic therapy risks a neuroleptic-malignant-syndrome-like withdrawal reaction.

Screen specifically for augmentation at each visit.
Baseline and periodic serum ferritin/iron studies.
Direct screening for impulse control disorders.
Monitor for excessive daytime somnolence/sudden sleep episodes; counsel about driving.
Orthostatic blood pressure, especially during titration.
Reassess need for CYP1A2-interacting medication changes that could alter ropinirole levels.
Hepatic function status given lack of formal hepatic-impairment dosing data.

Pregnancy: Limited human pregnancy safety data; animal studies showed adverse embryo-fetal developmental effects. Use only if potential benefit justifies potential fetal risk. RLS in pregnancy is generally managed first with iron repletion/non-pharmacologic measures.
Lactation: Ropinirole inhibits prolactin secretion and could inhibit lactation; human excretion into breast milk is unknown. Use during breastfeeding is generally not recommended.